Gerresheimer’s Fork in the Road: Insiders Bet Big While Regulators Circle

Gerresheimer shares fell 8.78% last week, but insider purchases and Goldman Sachs raising stake to 20% signal confidence. Technical resistance and accounting issues persist, with Centor sale in focus.

The German pharmaceutical packaging specialist Gerresheimer finds itself caught between two opposing forces. While the stock slumped 8.78% last week to close at €24.92 on Friday, a flurry of insider buying and a significant increase in Goldman Sachs’ reported stake suggest that major players see value where the broader market sees risk.

Goldman Sachs lifted its total voting rights position to 20.09% as of 11 May 2026, up from 19.80% previously. The structure is telling: 8.90% of the votes are tied directly to shares, while 11.19% are held via financial instruments. Such a disclosure does not automatically signal an intent to control, but it does confirm that one of Wall Street’s largest institutions is comfortable expanding its exposure at a moment when Gerresheimer is grappling with unresolved accounting issues.

Adding to the bullish signals, a Director’s Deal was filed on 12 May. AOC Gecko S.à r.l., an entity closely linked to supervisory board member Klaus Röhrig, purchased Gerresheimer shares on Xetra for a total of €7,670,705.79 at a price of €25.25 per unit. In a period when the company faces regulatory scrutiny and a delayed audit, a €7.7 million vote of confidence from an insider cannot be easily dismissed.

Yet the market as a whole remains deeply skeptical. Over the past twelve months, the stock has shed nearly 60% of its value, despite a sharp 41% recovery from its low over the last thirty days. That relief rally now appears to have stalled, with the weekly loss of 8.78% erasing a chunk of recent gains.

Technically, the picture is split. The short-term moving average sits at €21.03, while the long-term trend line is at €27.37. This leaves the stock trapped between the two, with any recovery attempts overshadowed by the massive overhead resistance that former trading levels represent. Analysts note that the latest bounce remains fragile until the company can provide clarity on its balance sheet.

Operationally, Gerresheimer is not standing still. At the Interpack trade fair, it showcased a partnership with Milliken & Company centered on the LeneX™ UltraGuard® technology, an additive system for HDPE packaging that improves moisture barrier performance by up to 40%. For pharmaceutical clients dealing with humidity-sensitive products, this is a meaningful step forward. The link builds on an existing collaboration between Milliken and Bormioli Pharma, a Gerresheimer subsidiary. But in the current climate, product news alone is not enough to shift the narrative.

The structural fix that investors are watching most closely is the planned sale of the US subsidiary Centor. Morgan Stanley has been mandated to run the process, and a deal is targeted before the end of 2026. Centor, which serves the US pharmacy market, was carried in the books at €292 million at the end of last year. Reports indicate that potential buyers have already stepped forward in the double digits, strengthening Gerresheimer’s negotiating hand — though a signed agreement remains elusive.

On the regulatory front, the heat is rising. Germany’s BaFin is investigating, among other items, lease liabilities with a book value of €65.5 million. Separately, the APAS is examining KPMG’s role regarding bill-and-hold transactions totalling €35 million. These probes continue to hang over the stock, and until they are resolved, the discount on Gerresheimer’s valuation is unlikely to close.

The company has bought itself some breathing room on the financing side. Banks and Schuldschein creditors have agreed to extend waivers until 30 September 2026, suspending the leverage-related covenants. That gives management a window to conclude the audit and push ahead with the Centor sale.

Management maintains its full-year guidance: revenue of around €2.3–2.4 billion and an adjusted EBITDA margin of roughly 18–19% for fiscal 2026. But those targets are conditional on a positive outcome from the BaFin review. The core tension is that while the underlying business is sending signals of stability, the accounting uncertainty keeps a lid on the share price.

June is the pivotal month. Gerresheimer plans to publish its audited annual and consolidated financial statements for fiscal 2025, followed shortly by the quarterly report. The annual general meeting, originally scheduled for 3 June, has been postponed. The half-year report is set for 14 July. Until then, the sustainability of any further stock recovery depends almost entirely on clean audit findings and clearer communication on the balance sheet. The insider purchases and Goldman’s increased position suggest that at least some deep-pocketed actors are betting that clarity will come.